GNLX Genelux Corporation

$2.74

Genelux Corporation (GNLX) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.4% since its last earnings release on August 13, 2026.

Genelux Missed Consensus Estimates
Thursday, August 13, 2026 · 4:20 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:15 PM ET
Earnings Whisper
-
vs ($0.20)
Rev est $11.8M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.74

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Genelux Corporation

Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus. Genelux Corporation is based in WESTLAKE VILLAGE, Calif.

Sector

Healthcare

Industry

Biotechnology